KOPRAN LTD

Operates as an integrated pharmaceutical company with two main businesses: Active Pharmaceutical Ingredients (APIs) manufactured through subsidiary Kopran Research Laboratories Limited (KRLL), and Formulations. The group sells APIs and formulations across more than 50 countries, with exports a major part of the revenue base. In FY26, consolidated revenue was ₹68,142 lakhs, Q4 FY26 revenue reached ₹23,402 lakhs (up 36% year-on-year and the highest ever quarterly figure), and Q4 EBITDA was ₹4,057 lakhs at a 17.34% margin. Materials accounted for 63.3% of revenue, making raw material sourcing — including an explicit strategy to reduce China dependence for APIs — the principal cost lever. A scheme of amalgamation to absorb Kopran Laboratories into the parent is in progress (NCLT-admitted), and the API subsidiary is raising ₹18.75 crore via a rights issue for working capital. Planned capacity additions include a new API and R&D facility at Panoli, Gujarat, and automation of formulations packing lines. Full-year FY26 net profit fell to ₹2,573 lakhs from ₹3,855 lakhs in FY25, weighed down by ₹1,595 lakhs of foreign exchange losses.